Table 2.

Follow-up and final disposition of subjects^a

	Women, n	Men, n
Total subjects	1,390	1,158
CD diagnosed by histology before enrolment	0	1
Abnormal composite TG2/DGP IgA/IgG, and TG2 IgA, or DGP IgA or IgG	51	56
Findings diagnostic/supportive of untreated CD
Histological diagnosis: Intestinal villous atrophy, crypt hyperplasia, and IELs
Prompted by current study, 2010	6	4
During standard medical care between 2004 and 2009	4	2
Serological diagnosis: confirmation of multiple CD serological abnormalities
No supporting histological evidence obtained	2	3
Treating doctor excluded CD because patient was asymptomatic	0	2
Findings equivocal for CD
Intestinal IELs +/− mild focal villous atrophy, or villous atrophy and crypt hyperplasia without IELs	0	3
Findings excluded/were not supportive of CD
Normal intestinal histology without serological testing	2	5
Serological exclusion: CD serological abnormalities not replicated	7	8
Genotyping exclusion: testing for HLA DQ2.5/8/2.2 negative	0	1
Follow-up not possible or not undertaken
Treating doctor did not investigate further as subject asymptomatic and/or performed blood tests unrelated to CD	1	5
Subject deceased and CD not diagnosed pre-mortem	8	5
Subject declined follow-up medical review	16	11
Subject could not be contacted; lost to follow-up	5	7
CD cases estimated by serogenetic modeling, range	12 to 26	12 to 16
Lower 95% CI for CD cases based on TG2+ EMA+	11	12

Abbreviations: CD, celiac disease; DGP, Deamidated gliadin-derived peptide; EMA, endomysial antibody; HLA, human leukocyte antigen; IEL, Intra-epithelial lymphocyte; Ig, immunoglobulin; TG, transglutaminase.

^aData are n, unless otherwise stated.